{
  "source": "PA-Med-Nec-Attruby.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2362-1\nProgram Prior Authorization/Medical Necessity\nMedication Attruby™ (acoramidis)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nAttruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type\nor variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular\ndeath and cardiovascular-related hospitalization.\n2. Coverage Criteriaa:\nA. Transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)\n1. Initial Authorization\na. Attruby will be approved based on all of the following criteria:\n(1) Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy\n(ATTR-CM)\n-AND-\n(2) One of the following:\n(a) Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)\n-OR-\n(b) Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of\nATTR amyloid deposits\n-OR-\n(c) All of the following:\ni. Echocardiagram or cardiac magnetic resonance imaging suggestive of\namyloidosis\n-AND-\nii. Radionuclide imaging (99mTc-DPD, 99mTc-PYP, or 99m Tc-HMDP) showing\ngrade 2 or 3 cardiac uptake*\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\niii. Absence of light chain amyloidosis\n-AND-\n(3) Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart\nfailure\n-AND-\n(4) Physician attests that the patient has an N-terminal pro-B-type naturetic peptide (NT-\nproBNP) level that, when combined with signs and symptoms, is considered\ndefinitive for a diagnosis of ATTR-CM\n-AND-\n(5) One of the following:\n(a) History of heart failure, with at least one prior hospitalization for heart failure\n-OR-\n(b) Presence of signs and symptoms of heart failure (e.g., dyspnea, edema)\n-AND-\n(6) Prescribed by or in consultation with a cardiologist\n-AND-\n(7) Patient is not receiving Attruby in combination with an RNA-targeted therapy for\nATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisira",
    "d by or in consultation with a cardiologist\n-AND-\n(7) Patient is not receiving Attruby in combination with an RNA-targeted therapy for\nATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi\n(inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Attruby will be approved based on all of the following criteria:\n(1) Documentation that the patient has experienced a positive clinical response to\nAttruby (e.g., improved symptoms, quality of life, slowing of disease progression,\ndecreased hospitalizations, etc.)\n-AND-\n(2) Documentation that patient continues to have New York Heart Association (NYHA)\nFunctional Class I, II, or III heart failure\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(3) Prescribed by or in consultation with a cardiologist\n-AND-\n(4) Patient is not receiving Attruby in combination with an RNA-targeted therapy for\nATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi\n(inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*May require prior authorization and notification\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Attruby [package insert]. BridgeBio Pharma, Inc: Palo Alto, CA; November 2024.\n2. Fontana, M. Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis.\nUpToDate. Dardas, T: UpToDate Inc. https://www.uptodate.com (Accessed on",
    "a, Inc: Palo Alto, CA; November 2024.\n2. Fontana, M. Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis.\nUpToDate. Dardas, T: UpToDate Inc. https://www.uptodate.com (Accessed on December 2,\n2024).\n3. Fontana, M. Cardiac amyloidosis: Treatment and prognosis. UpToDate. Dardas, T: UpToDate\nInc. https://www.uptodate.com (Accessed on December 2, 2024).\n4. Ruberg FL, Maurer MS. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA\n2024; 331:778.\n5. Kittleson, M, Ruberg, F. et al. 2023 ACC Expert Consensus Decision Pathway on\nComprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the\nAmerican College of Cardiology Solution Set Oversight Committee. JACC. 2023 Mar, 81 (11)\n1076–1126.\nProgram Prior Authorization/Medical Necessity - Attruby™ (acoramidis)\nChange Control\n1/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}